NASDAQ:PPH

VanEck Vectors Pharmaceutical ETF Stock Forecast, Price & News

$68.37
+0.54 (+0.80 %)
(As of 04/9/2021 12:00 AM ET)
Add
Today's Range
$67.95
Now: $68.37
$68.37
50-Day Range
$66.06
MA: $68.49
$69.93
52-Week Range
$56.68
Now: $68.37
$71.15
Volume6,600 shs
Average Volume87,618 shs
Market Capitalization$217.96 million
P/E RatioN/A
Dividend Yield1.65%
BetaN/A

Basic Details

Issuer Van Eck
Fund NameVanEck Vectors Pharmaceutical ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:PPH
Inception Date12/20/2011
Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkMarket Vectors US Listed Pharmaceutical 25 Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionGlobal

Fund Statistics

Assets Under Management$172.45 million
Average Daily Volume$38,061.10
Discount/Premium0.06%

ETF Expenses

Management Fee0.35%
Other Expenses0.05%
Total Expenses0.40%
Fee Waiver-0.05%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorVan Eck Associates Corporation
AdvisorVan Eck Associates Corporation
CustodianThe Bank of New York Mellon Corporation
DistributorVan Eck Securities Corporation
Transfer AgentThe Bank of New York Mellon Corporation
Trustee
Lead Market MakerIMC Chicago

Geographic Exposure of PPH

Currency Exposure of PPH

Sector Exposure of PPH

Industry Exposure of PPH

$68.37
+0.54 (+0.80 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PPH News and Ratings via Email

Sign-up to receive the latest news and ratings for PPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH) Frequently Asked Questions

What stocks does MarketBeat like better than VanEck Vectors Pharmaceutical ETF?

Wall Street analysts have given VanEck Vectors Pharmaceutical ETF a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VanEck Vectors Pharmaceutical ETF wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VanEck Vectors Pharmaceutical ETF?

VanEck Vectors Pharmaceutical ETF saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 845,800 shares, an increase of 102.7% from the February 28th total of 417,200 shares. Based on an average trading volume of 94,000 shares, the short-interest ratio is currently 9.0 days.
View VanEck Vectors Pharmaceutical ETF's Short Interest
.

How has VanEck Vectors Pharmaceutical ETF's stock been impacted by Coronavirus?

VanEck Vectors Pharmaceutical ETF's stock was trading at $56.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PPH shares have increased by 20.7% and is now trading at $68.37.
View which stocks have been most impacted by COVID-19
.

How often does VanEck Vectors Pharmaceutical ETF pay dividends? What is the dividend yield for VanEck Vectors Pharmaceutical ETF?

VanEck Vectors Pharmaceutical ETF announced a quarterly dividend on Wednesday, March 31st. Shareholders of record on Monday, April 5th will be paid a dividend of $0.35 per share on Thursday, April 8th. This represents a $1.40 annualized dividend and a dividend yield of 2.05%. The ex-dividend date of this dividend is Thursday, April 1st. This is a positive change from VanEck Vectors Pharmaceutical ETF's previous quarterly dividend of $0.27.
View VanEck Vectors Pharmaceutical ETF's dividend history
.

Is VanEck Vectors Pharmaceutical ETF a good dividend stock?

VanEck Vectors Pharmaceutical ETF pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.65%.
View VanEck Vectors Pharmaceutical ETF's dividend history.

What is Bruce Gordon's approval rating as VanEck Vectors Pharmaceutical ETF's CEO?

38 employees have rated VanEck Vectors Pharmaceutical ETF CEO Bruce Gordon on Glassdoor.com. Bruce Gordon has an approval rating of 98% among VanEck Vectors Pharmaceutical ETF's employees. This puts Bruce Gordon in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of VanEck Vectors Pharmaceutical ETF own?

What is VanEck Vectors Pharmaceutical ETF's stock symbol?

VanEck Vectors Pharmaceutical ETF trades on the NASDAQ under the ticker symbol "PPH."

How do I buy shares of VanEck Vectors Pharmaceutical ETF?

Shares of PPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VanEck Vectors Pharmaceutical ETF's stock price today?

One share of PPH stock can currently be purchased for approximately $68.37.

How much money does VanEck Vectors Pharmaceutical ETF make?

VanEck Vectors Pharmaceutical ETF has a market capitalization of $217.96 million.


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.